（编辑 袁冠琳） 证券日报网讯 1月30日，广生堂在互动平台回答投资者提问时表示，本次在AASLD年会上的报告，是 公司在乙肝治疗领域创新药研发进展的一次重要展示，有助于该研究成果获得国际肝病学术领域的关 注，促进了友好的国际交流和合作探讨。公司将继续稳步推进相关乙肝创新药临床研发工作，依规及时 履行创新药进展的信息披露义务。 ...

Core Viewpoint - The company Guangshentang (300436) stated that the U.S. tariff policy on pharmaceuticals has not materially affected the research and development progress of its drug GST-HG141, and that its production and operations are normal [1] Group 1 - The company management remains focused on its core business and is steadily advancing the research and development of innovative hepatitis B drugs [1]